Probe-level performance of Xpert MTB/RIF versus phenotypic culture for rifampicin resistance detection and a triage algorithm based on 3,360 clinical specimens in China
Open Access
- 28 July 2026
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Abstract
Background: The Xpert MTB/RIF (Xpert) assay is a cornerstone for the rapid detection of rifampicin resistance. However, discordant results between Xpert and phenotypic drug susceptibility testing (pDST) present diagnostic challenges, particularly in regions with genetically diverse Mycobacterium tuberculosis populations. This study aimed to evaluate the performance of Xpert at the probe level to resolve such discrepancies and to inform an optimized diagnostic workflow. Methods: Using a retrospective cohort of 3,360 clinical specimens from a high-burden setting in China, we compared Xpert results with pDST as the reference standard. We then performed a stratified analysis based on specific probe mutation patterns to determine their predictive value for phenotypic resistance. Results: Overall, Xpert demonstrated substantial agreement with pDST ( κ = 0.722, 95% CI: 0.685–0.759), exhibiting a sensitivity of 80.4% and a specificity of 95.8%. However, concordance was highly dependent on the specific probe mutation. Mutations in Probe E were strongly predictive of phenotypic resistance (Positive Predictive Value: PPV: 91.4%). In contrast, The mutations detected by Probe ΔCt and Probe A exhibited a low PPV of only 28.0% and 14.3%, respectively. Based on these findings, we propose a diagnostic triage strategy: results indicating Probe E mutations can reliably guide immediate treatment adjustments, whereas isolated ProbeΔCt resistance, or Probe A mutations, warrant confirmatory pDST before initiating second-line regimens. Conclusion: The clinical interpretation of Xpert results requires a nuanced understanding of probe-specific mutation patterns. Our probe-stratified analysis and the resulting triage algorithm provide a practical framework for optimizing the management of rifampicin-resistant tuberculosis (RR-TB). This approach effectively balances the need for diagnostic speed with therapeutic accuracy in programmatic settings.Keywords
This publication has 20 references indexed in Scilit:
- Laboratory Evaluation of a Lateral-Flow Cell for Molecular Detection of First-Line and Second-Line Antituberculosis Drug ResistanceJournal of Clinical Microbiology, 2020
- Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility TestingOpen Forum Infectious Diseases, 2020
- Efficacy Of Line Probe Assay In Detection Of Drug-Resistant Pulmonary Tuberculosis In Comparison With GeneXpert And Phenotypic Methods In Iran And Genetic Analysis Of Isolates By MIRU-VNTRInfection and Drug Resistance, 2019
- Drug-resistant tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–2017Public Health Action, 2019
- Interpreting very low Mycobacterium tuberculosis detected on Xpert Mycobacterium tuberculosis/rifampicinLung India, 2019
- Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysisThe Lancet, 2018
- Mixed Mycobacterium tuberculosis Complex Infections and False-Negative Results for Rifampin Resistance by GeneXpert MTB/RIF Are Associated with Poor Clinical OutcomesJournal of Clinical Microbiology, 2014
- Results from early programmatic implementation of Xpert MTB/RIF testing in nine countriesBMC Infectious Diseases, 2014
- Xpert ® MTB/RIF Assay: Development, Evaluation and Implementation of a New Rapid Molecular Diagnostic for Tuberculosis and Rifampicin ResistanceFuture Microbiology, 2011
- Evaluation of the Analytical Performance of the Xpert MTB/RIF AssayJournal of Clinical Microbiology, 2010